Drug Combination Details
General Information of the Combination (ID: C28568) | |||||
---|---|---|---|---|---|
Name | Arsenic trioxide NP Info | + | Megestrol acetate Drug Info | ||
Structure | + | ||||
Disease |
Hepatocellular carcinoma
[ICD-11: 2C12]
|
Investigative | [1] |
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
---|---|---|---|---|---|---|
α. Enhancing Drug Efficacy by This Combination | ||||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Experiment 1 Reporting the Effect of This Combination | [1] | |||||
Molecule(s)
Regulation |
Up-regulation | Cleavage | CASP3 | Molecule Info |
Pathway MAP
|
|
Up-regulation | Phosphorylation | ERK1 | Molecule Info |
Pathway MAP
|
||
Up-regulation | Phosphorylation | ERK2 | Molecule Info |
Pathway MAP
|
||
Up-regulation | Phosphorylation | JNK1 | Molecule Info |
Pathway MAP
|
||
Up-regulation | Phosphorylation | p38 beta | Molecule Info |
Pathway MAP
|
||
Up-regulation | Cleavage | PARP1 | Molecule Info |
Pathway MAP
|
||
In-vitro Model | Hep-G2 | CVCL_0027 | Hepatocellular carcinoma | Homo sapiens | ||
BEL-7402 | CVCL_5492 | Human hepatocellular carcinoma | Homo sapiens | |||
In-vivo Model | HepG2 cells were collected in 0.2 ml of PBS, and the cell suspensions were then injected subcutaneously into five-week-old BALB/C male nude mice (5*106 cells per mouse). | |||||
Experimental
Result(s) |
MA/ATO combined treatment enhanced antitumor efficacy. |
References | ||||
---|---|---|---|---|
Reference 1 | Enhanced antitumor activity of combined megestrol acetate and arsenic trioxide treatment in liver cancer cells. Exp Ther Med. 2018 Apr;15(4):4047-4055. |